Aaron P Schultz, Ph.D.
Neurology, Research Institute
Neurology, Massachusetts General Hospital
Assistant Professor of Neurology
Harvard Medical School
|PhD University of Connecticut/Farmington 2009|
My research focus is on neuroimaging in the context of aging and neurodegenerative disease with a special focus on Alzheimer’s disease (AD), with a particular emphasis on preclinical AD. I have special interests in fcMRI and PET based molecular markers of amyloid and tau pathology, with translational applications to clinical trials. I currently lead the Functional Neuroimaging Group (FNG) for the Anti-Amyloid in Asymptomatic AD (A4) clinical trial, and I am the project leader for the Harvard Aging Brain Study (HABS) dynamic networks project and co-leader of the HABS data core. My neuroimaging experience covers multiple MR and PET modalities including task-based fMRI, functional connectivity MRI (fcMRI), structural MRI, FDG-PET (metabolism), PiB-PET (amyloid), FBP-PET (amyloid, aka AV45), FTP-PET (tau; aka T807 / AV1451), and MK6240-PET. My skill set encompasses statistical knowledge; sophisticated programming skills; advanced neuroimaging data analysis; computer science; and informatics. I have a strong focus on data analytics, informatics, and methods development, with an eye towards improving imaging biomarkers to better understand neurodegenerative diseases and to create more useful measures for translational clinical research and clinical trials. Most recently I have focused on relationships between in-vivo Tau-PET measures and both structural and functional MRI, as well as assessing the ability of fcMRI measures to predict and track cognitive decline. I also have a strong interest in understanding the consequences of amyloid pathology and how it contributes to neuronal dysfunction and eventual neuronal loss which is the key focus of my NIH R21 project, Examining the dynamic and metabolic underpinnings of functional connectivity in preclinical Alzheimer's disease.